

# ACTIN Report (research use only)

PATIENT  
EXAMPLE-LUNG-01  
REPORT DATE  
17-Sep-2025

Gender: **Female** | Birth year: **1975** | WHO: **1**

Tumor: **Lung adenocarcinoma** | Lesions: **Liver, Lung** | Stage: **IV**

## Clinical summary

Relevant systemic treatment history      **6/2023-1/2025    Osimertinib**

## Recent molecular results

### Hartwig WGS (22-Feb-2025)

Biopsy location	<b>Lung (purity 50%)</b>
Molecular tissue of origin prediction	<b>Lung: Non-small cell: LUAD (98%)</b>
Tumor mutational load / burden	<b>TML 160 / TMB 14 mut/Mb</b>
Microsatellite (in)stability	<b>Stable</b>
HR status	<b>Proficient (0)</b>
Driver mutations	<b>EGFR C797S, EGFR L858R, KRAS G12C, KRAS G12D</b>
Amplified genes	<b>None</b>
Deleted genes	<b>TP53 del</b>
Homozygously disrupted genes	<b>None</b>
Gene fusions	<b>MET(exon13)::MET(exon15) fusion</b>
Driver virus	<b>None</b>

## Trial-relevant IHC results

PD-L1      **Score > 50%**

## Phase 2/3+ trials in NL that are open and potentially eligible (2 trials)

Trial	Cohort	Molecular	Sites	Warnings
<u><a href="#">METC 04</a></u> <u><a href="#">TEDR1</a></u> <u>(Phase 2)</u>	Lung cancer C797S cohort	EGFR C797S	NKI-AvL	None
<u><a href="#">EGFR-C797S-Trial</a></u> <u>(Phase 2)</u>	<i>EGFR C797S</i>	<i>EGFR C797S</i>	<i>Elisabeth-Tweesteden Ziekenhuis</i>	

Trials matched solely on molecular event and tumor type (no clinical data used) are shown in italicized, smaller font.

## Phase 1/2 (or unknown phase) trials in NL that are open and potentially eligible (3 trials)

Trial	Cohort	Molecular	Sites	Warnings
<u><a href="#">METC 02</a></u> <u><a href="#">KAYRAS</a></u> <u>(Phase 1/2)</u>	Dose expansion - monotherapy - NSCLC	KRAS G12D, PD-L1 >= 50.0	Erasmus MC	Variant(s) G12D in KRAS but subclonal likelihood of > 50%
<b>METC 01</b> IEMOEN (Phase 1)	Dose escalation - monotherapy (no slots)	None		Has not exhausted SOC (at least platinum doublet remaining)
<u><a href="#">EGFR-L858R-Trial</a></u> <u>(Phase 1)</u>	<i>EGFR L858R</i>	<i>EGFR L858R</i>	<i>Elisabeth-Tweesteden Ziekenhuis</i>	

Trials matched solely on molecular event and tumor type (no clinical data used) are shown in italicized, smaller font.

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

1/6 Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).

# ACTIN Report (research use only)

PATIENT  
EXAMPLE-LUNG-01  
REPORT DATE  
17-Sep-2025

## International trials that are open and potentially eligible (1 trial)

Trial	Cohort	Molecular	Sites
<a href="#"><u>KRAS-G12C-TRIAL-DE (Phase 1)</u></a>	KRAS G12C	KRAS G12C	Germany: Stuttgart

Trials in this table are matched solely on molecular event and tumor type (clinical data excluded).

1 trial filtered due to trials recruiting nationally for the same molecular target. See Other Trial Matching Results for filtered matches.

# ACTIN Report (research use only)

PATIENT  
EXAMPLE-LUNG-01  
  
REPORT DATE  
17-Sep-2025

## Molecular Details

### Hartwig WGS (EXAMPLE-LUNG-01-T, 22-Feb-2025)

#### General

Purity	Ploidy	TML Status	TMB Status	MS Stability	HR Status	DPYD	UGT1A1
50%	2.3	High (160)	High (14)	Stable	Proficient (0)	*1_HOM (Normal function)	*1_HOM (Normal function)

#### Predicted tumor origin

##### 1. Lung: Non-small cell: LUAD

Combined prediction score	98%
---------------------------	-----

This score is calculated by combining information on:

(1) SNV types	60%
(2) SNV genomic localisation distribution	70%
(3) Driver genes and passenger characteristics	80%

Other cohorts have a combined prediction of 2% or lower

#### Key drivers

Type	Driver	Trials (Locations)	Trials in Hartwig	Best evidence in External	Resistance in External
Mutation (gain of function)	EGFR L858R (2/4 copies)		NCT00000006	Approved	
Mutation (gain of function)	EGFR C797S (1/4 copies)	TEDR1 (NKI-AvL)	NCT00000008	Pre-clinical	
Mutation (gain of function)	KRAS G12D (0.3/2 copies)*	KAYRAS (Erasmus MC)			
Mutation (gain of function)	KRAS G12C (0.3/2 copies)*		NCT00000009		
Deletion	TP53 del				

The table continues on the next page

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

# ACTIN Report (research use only)

PATIENT  
EXAMPLE-LUNG-01  
REPORT DATE  
17-Sep-2025

Continued from the previous page

Type	Driver	Trials (Locations)	Trials in Hartwig	Best evidence in External	Resistance in External
Known fusion	MET(exon13)::MET(exon15) fusion Domain(s) kept: Tyrosine Kinase Domain(s) lost: Juxtamembrane				

\* Variant has > 50% likelihood of being sub-clonal

## Other drivers or relevant events

None

## IHC results

PD-L1

Score > 50%

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

# ACTIN Report (research use only)

PATIENT  
EXAMPLE-LUNG-01  
REPORT DATE  
17-Sep-2025

## Clinical Details

### Clinical summary

Relevant systemic treatment history	6/2023-1/2025	Osimertinib
Relevant other oncological history		<b>None</b>
Previous primary tumor		<b>None</b>
Relevant non-oncological history	2023	Rheumatoid arthritis

### Patient current details (20-Feb-2025)

Unresolved toxicities grade => 2	<b>None</b>
LVEF	50%
Known allergies	<b>None</b>
Recent surgeries	01-Aug-2024 Cholecystectomy

### Tumor details (20-Feb-2025)

Measurable disease	<b>Yes</b>
Known lesions	<b>Liver, Lung</b>
No lesions present	<b>CNS, Brain, Bone, Lymph node</b>

### Active medication details

Medication	Administration route	Start date	Stop date	Dosage	Frequency
St. John's Wort	Oral	01-Feb-2023		300 MILLIGRAMS	1 / 2 DAYS

### Blood transfusions

Product	Date
ERTHROCYTES_FILTERED	20-Sep-2024

## Trial Matching Details

### Filtered trials potentially eligible based on molecular results which are potentially recruiting (1 trial)

Trial	Cohort	Molecular	Sites
<a href="#">EGFR-BE (Phase 1)</a>	<i>EGFR L858R</i>	<i>EGFR L858R</i>	<i>Belgium: Brussels</i>

### Trials and cohorts that are potentially eligible, but are closed (1 trial)

Trial	Cohort	Molecular	Sites	Warnings
<a href="#">METC 01 IEMOEN (Phase 1)</a>	Dose expansion - monotherapy	None		Has not exhausted SOC (at least platinum doublet remaining)

### Trials and cohorts that are considered ineligible (4 cohorts from 3 trials)

Trial	Cohort	Molecular	Ineligibility reasons
<a href="#">METC 02 KAYRAS (Phase 1/2)</a>	Dose expansion - monotherapy - Colorectum	KRAS G12D, PD-L1 >= 50.0	No colorectal cancer
<a href="#">METC 03 NO-SEE797ES</a>	Dose escalation - monotherapy	EGFR C797S	C797S in EGFR in canonical transcript
<a href="#">METC 05 PICKME3CA</a>	<i>Applies to all cohorts below</i>  Dose expansion - monotherapy - NSCLC <i>(closed)</i> Dose expansion - monotherapy - Other cancer types <i>(closed)</i>	None	No PIK3CA activating mutation(s)  Tumor belongs to DOID term(s) lung non-small cell carcinoma

### Trials and cohorts that are not evaluable or ignored (0 trials)

None